Moreover, in human patients with advanced melanomas, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma, approximately a significant percentage of CD8+ tumor-infiltrating lymphocytes express both TIM-3 and PD-I [71]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.